Eton Pharmaceuticals Inc. (ETON) announced Tuesday that it has out-licensed commercial rights to Increlex in territories outside of the U.S. to Esteve Pharmaceuticals, S.A.
Esteve will license the ex-U.S. rights for up to ten years and will also be receiving an option to acquire the international rights in the future. Eton will supply product to Esteve at a fixed transfer price, and the transaction does not impact the company's expectation to exit 2025 at around $80 million annual revenue run rate.
The company noted that Esteve has the global infrastructure and established presence necessary to successfully commercialize Increlex in countries outside the U.S.
With the deal, Eton, the company focused on developing treatments for rare diseases, expects to focus its efforts on its compelling growth opportunities within the U.S., including its three rare disease product launches planned for 2025.
The deal also eliminates the need for significant infrastructure investments that would have been required to commercialize Increlex outside the U.S.
For comments and feedback: editorial@rttnews.com